Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the promising data from CTLA-4 drugs, suggesting potential investment opportunities in related areas [3][5] - The pharmaceutical index experienced a slight decline of 0.14% from December 15 to December 19, 2025, but showed a relative outperformance of 0.14% against the CSI 300 index [5] - The report emphasizes the importance of innovative drugs as a key investment theme for 2026, with a focus on companies that are expected to show clear performance trends and potential reversals in operations [5][41] Summary by Sections 1. CTLA-4 Target - CTLA-4 is identified as a significant immune checkpoint that can inhibit T cell activation, presenting potential value in cancer immunotherapy [8][9] - The CTLA-4 monoclonal antibody Gotistobart shows promising clinical trial results for squamous non-small cell lung cancer (sqNSCLC) patients who are resistant to immunotherapy [14][15] - Gotistobart's innovative mechanism targets Treg cells in the tumor microenvironment, potentially leading to a new paradigm in tumor immunotherapy [20][24] 2. Industry Perspective - The report maintains that innovative drugs should be the main focus for the year, while also considering manufacturing exports and aging-related consumption as relatively undervalued assets [25][41] - The pharmaceutical index has shown a year-to-date increase of 14.49%, with a notable number of stocks experiencing significant gains [25][26] - The report suggests that the Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs opening new growth avenues for companies [41][42] 3. Investment Recommendations - Recommended stocks include innovative drug companies such as Xinyi Tai, Zai Jian Pharmaceutical, and others, as well as companies in the medical device sector [5][45] - The report advises focusing on companies with strong performance trends and those expected to benefit from the aging population and outpatient consumption [42][44] - The report also highlights the potential of AI in the pharmaceutical sector, suggesting that related stocks may perform well in the coming years [42][44]

泽璟制药(688266.SH)发布公告，公司于2025年12月19日向香港联交所递交了发行H股股票并在香港联交 所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请材料。该申请材料为公 司按照香港证券及期货事务监察委员会(简称"香港证监会")及香港联交所的要求编制和刊发，为草拟版 本，其所载资料可能会适时作出更新及修订，投资者不应根据其中的资料作出任何投资决定。 ...

Core Viewpoint - Suzhou Zelgen Biopharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CICC as its sole sponsor, indicating its intent to expand its capital base for further development in the biopharmaceutical sector [1] Group 1: Company Overview - Zelgen Biopharmaceutical is a comprehensive biopharmaceutical company focused on the discovery, research and development, and commercialization of innovative small molecules and biological agents [1] - The company strategically focuses on three therapeutic areas: oncology, autoimmune diseases, and hemostasis/blood disorders [1] Group 2: Product Portfolio - Zelgen Biopharmaceutical has a product portfolio that includes marketed drugs, late-stage clinical candidates, and early-stage innovative discovery projects [1] - The company currently has three marketed drugs: - Zepu Sheng, the first domestically developed small molecule multi-target drug for first-line treatment of advanced liver cancer in China - Zepu Ping, the first domestically developed innovative JAK inhibitor for the treatment of myelofibrosis - Zepu Ning, the only recombinant human thrombin developed and successfully commercialized using recombinant DNA technology in China [1]

Group 1 - The core point of the article is that Suzhou Zelgen Biopharmaceuticals Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with CICC as the sole sponsor [1] - Zelgen Biopharmaceuticals is a comprehensive biopharmaceutical company focused on the discovery, research and commercialization of innovative small molecules and biological agents, with strategic focus on oncology, autoimmune diseases, and hemostasis/blood diseases [1] - The product portfolio includes three marketed drugs: Zepsu, the first domestically developed small molecule multi-target drug for first-line treatment of advanced liver cancer in China; Zepsin, the first innovative JAK inhibitor for treating myelofibrosis developed in China; and Zepsinogen, the only recombinant human thrombin developed and commercialized using recombinant DNA technology in China [1]

Group 1 - Suzhou Zelgen Biopharmaceuticals Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CICC as the sole sponsor [1][3] - The company is a comprehensive biopharmaceutical enterprise focused on the discovery of innovative small molecules and biological therapies, with strategic emphasis on oncology, autoimmune diseases, and hemostatic blood disorders [1] - Zelgen Biopharmaceuticals has a product portfolio that includes three marketed drugs: Zepsin, the first domestically developed small molecule multi-target drug for first-line treatment of advanced liver cancer in China; Zeppin, the first domestically developed innovative JAK3 formulation for treating myelofibrosis; and Zeplin, the only recombinant human thrombin developed and commercialized using recombinant DNA technology in China [1]

据港交所文件，苏州泽璟生物制药股份有限公司向港交所提交上市申请书，独家保荐人为中金公司。 ...

Group 1 - The core viewpoint of the news highlights a significant increase in the Shanghai Stock Exchange's Sci-Tech Innovation Board Innovative Drug Index, with a rise of 3.26% as of December 19, 2025, driven by strong performances from constituent stocks such as Chengdu Xian Dao (up 10.44%) and Yifang Bio (up 9.82%) [1] - The recent announcement by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security regarding the 2025 National Basic Medical Insurance Drug List includes 114 new drugs, of which 50 are innovative drugs, marking an 88% success rate, a 12 percentage point increase from 2024 [3] - The total R&D investment by innovative drug companies on the Sci-Tech Innovation Board reached a new high in the first three quarters of 2025, with a year-on-year increase of over 10% and an R&D intensity of 42%, significantly surpassing the overall level of A-shares [4] Group 2 - The collaboration between Innovent Biologics and Takeda Pharmaceutical regarding three innovative cancer drugs has been completed, with Innovent receiving a total upfront payment of $1.2 billion, including a strategic investment of $100 million, and potential milestone payments of up to $10.2 billion [5] - The CXO industry is entering a new high prosperity cycle, driven by external improvements, including overseas interest rate cuts and domestic recovery, with a focus on innovative drug companies benefiting from policy support and innovation upgrades [6] - The implementation of the "Medicare + Commercial Insurance" multi-layered medical security system is seen as a substantial breakthrough, with nearly 90% of new drugs approved by Sci-Tech Board biopharmaceutical companies included in the insurance list [3][4]

Market Overview - The Shanghai Composite Index closed at 3871.44 points, above the annual line, with an increase of 1.22% [1] - The total trading volume of A-shares reached 18224.48 billion yuan [1] Stocks Breaking Annual Line - A total of 118 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] - Stocks with the highest deviation rates include: - Jiaying Pharmaceutical (8.17%) - Kaiwang Technology (7.31%) - Chuanhuan Technology (6.60%) [1] Detailed Stock Performance - The following stocks have notable performance metrics: - Jiaying Pharmaceutical: Today's increase of 9.96%, turnover rate of 5.15%, latest price at 7.40 yuan [1] - Kaiwang Technology: Today's increase of 15.65%, turnover rate of 8.96%, latest price at 38.87 yuan [1] - Chuanhuan Technology: Today's increase of 8.66%, turnover rate of 12.99%, latest price at 35.76 yuan [1] - Additional stocks with significant performance include: - Yongji Co. (6.07% deviation) - Runpu Food (5.64% deviation) - Kunlun Wanwei (5.37% deviation) [1]

Core Points - The Shanghai Composite Index closed at 3867.04 points, above the annual line, with an increase of 1.10% [1] - The total trading volume of A-shares reached 1.367165 trillion yuan [1] - A total of 74 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - The stocks with the highest deviation rates include Hanxin Technology (10.28%), Jiaying Pharmaceutical (8.17%), and Runpu Food (6.44%) [1] - Other stocks that just crossed the annual line include ST Qibu, Yinghuatech, and Jiangxi Changyun, which have lower deviation rates [1] Trading Data - The trading performance of selected stocks shows significant daily changes, with Hanxin Technology leading with a daily increase of 13.96% and a turnover rate of 26.99% [1] - Jiaying Pharmaceutical and Runpu Food also showed strong daily increases of 9.96% and 9.35%, respectively [1] Additional Stock Information - Other notable stocks with positive performance include Yongji Co. (7.50%), Kaiwang Technology (13.86%), and Chuanhuan Technology (7.57%) [1] - The table lists various stocks with their respective trading data, including daily change percentages, turnover rates, annual line prices, latest prices, and deviation rates [1][2]

Core Insights - The A-share market has shown a fluctuating upward trend since 2025, with the pharmaceutical and biotechnology sector performing exceptionally well, dominating the top ten stock fund rankings in the first half of the year [2] - Jin Xiaofei, a representative mid-generation fund manager at Penghua Fund, has achieved remarkable performance with his managed funds, utilizing a unique "dual-line resonance" framework to navigate crowded sectors [2][3] Investment Performance - Jin Xiaofei has been with Penghua Fund since July 2012, accumulating a tenure of 9 years and 174 days, managing assets totaling 5.375 billion yuan, with a best-term return of 239.59% [3] - The Penghua Medical Technology Stock A fund, under Jin's management, has shown significant excess returns, with a total return of 74.19% since its inception on June 2, 2015, and a return of 73.03% this year [5] - The Penghua Innovation Upgrade Mixed A fund has also performed well, with a year-to-date return of 88.72% and a one-year return of 74.60% [15] Investment Strategy - Jin's investment strategy is centered on "fundamental trend investing," integrating a dual-dimensional analysis framework that focuses on both visible driving factors and market sentiment [3][4] - The "bright line" strategy emphasizes significant industry changes, while the "dark line" strategy identifies undervalued opportunities through reverse analysis of market emotions and capital flows [4] - Jin's approach includes a three-dimensional decision-making framework that considers long-term, mid-term, and short-term performance metrics to ensure robust investment logic [14][16] Stock Holdings and Performance - The fund has made strategic purchases in various stocks, including: - 1,126,260 shares of Nuocheng Jianhua, which saw a price increase of 213% during the holding period [7] - 217,760 shares of Dizhe Pharmaceutical, with a price increase of 90.49% [9] - 119,040 shares of Baijishenzhou, which appreciated by 257% [11] - 211,230 shares of Rongchang Bio, with a price increase of 121% [13] - The fund's holdings in stocks like Hailan Pharmaceutical and Zexing Pharmaceutical also demonstrated significant price increases during their respective holding periods [18][20] Market Outlook - Jin Xiaofei anticipates a new investment cycle in the pharmaceutical sector, with institutional holdings recovering from historical lows, and emphasizes the importance of beta opportunities in the current market [5][16] - The need for continuous optimization of risk control systems is highlighted, as the industry faces increasing competition and innovation [25]